Table 1.
True PAE |
Borderline PAE |
||
---|---|---|---|
AE | Biological agent | AE | Biological agent |
Psoriasis | Anti-TNF-α Rituximab Tocilizumab Ustekinumab |
Uveitis | Anti-TNF-α (etanercept) |
Crohn's disease and/or ulcerative colitis | Anti-TNF-α (etanercept) | Scleritis | Anti-TNF-α |
Hidradenitis suppurativa | Anti-TNF-α (adalimumab) Rituximab |
Sarcoidosis | Anti-TNF-α (etanercept) |
Granuloma annulare | Anti-TNF-α | ||
Interstitial granulomatous dermatitis | Anti-TNF-α | ||
Vasculitis | Anti-TNF-α | ||
Alopecia areata | Anti-TNF-α | ||
Vitiligo | Anti-TNF-α ustekinumab |
AE adverse events; PAE, paradoxical adverse events; TNF, tumour necrosis factor.